1 / 36

IDSA Clinical Practice Guidelines for the Treatment of MRSA

IDSA Clinical Practice Guidelines for the Treatment of MRSA. R. Dinny Weber, M.D. 6/30/11. R. Dinny Weber, M.D. Financial Disclosure 6/28/2011

delling
Download Presentation

IDSA Clinical Practice Guidelines for the Treatment of MRSA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. IDSA Clinical Practice Guidelines for the Treatment of MRSA R. Dinny Weber, M.D. 6/30/11

  2. R. Dinny Weber, M.D. • Financial Disclosure • 6/28/2011 • neither I, nor any member of my immediate family, within the last 12 months, have had a financial relationship with any proprietary entity producing health care goods or services.

  3. Prevention has obvious advantages • No pt has to endure the risk and suffering of infection (and treatment) • Prevention eases the pressure on antibiotics • Cost • Prevention just isn’t as sexy

  4. Management of Skin and Soft Tissue Infections • MRSA now is frequently community-acquired • This has led to a dramatic increase in ER visits and admissions for SSTI s • One study found 25.9% of outpt. S. aureus was MRSA (Am. J Infect Control 2003;53) • 74% since 2001 at a Houston pediatric hospital

  5. Cutaneous Abscess • Incision and Drainage is the cornerstone of treatment. • Cure rate is 85-90% • Value of antibiotics is less clear…in one study anitibiotic choice did not change outcome. • In two studies (adult and peds) TMS and Placebo were equivalent • Two other studies suggested benefit of ABX

  6. Cutaneous Abscesses • Moist heat facilitates drainage and may be adequate for small furuncles • Impetigo and secondarily infected lesions may respond to topical mupirocin 2%

  7. When to use Abx with I & D • Severe or extensive dz • Rapid progression with associated cellulitis • Comorbidities • Tough to drain • Lack of response to I & D alone • TOXICITY of the pt

  8. Cellulitis • Not all red skin is cellulitis • Purulent? ( i.e. purulent drainage or exudate) • Treat empirically for MRSA. May not need to cover strep • Non-purulent? Cover strep. Add MRSA coverage if no response (timing?) or toxic

  9. Purulent Cellulitis • Pts in 11 US EDs: 59% MRSA, 17% MSSA & 2.6% Beta strep

  10. Non-Purulent Cellulitis • Hard to define etiology • Pre- CA-MRSA era Beta strep and MSSA • Only one prospective study of non-culturable cellulitis in inpts. Beta strep were responsible for 73% ( by serologic tests). 27% not ID’d • Clinical response to Beta lactam rx 96%

  11. Oral Antibiotic Regimens for SSTI • Clindamycin (69% of local MRSA is sensitive) • TMS • TCN • Linezolid • Add Beta lactam to cover strep if TMS or TCN • Rifampin not recommended

  12. Parenteral Regimens for SSTI - adults • Use for sicker patients…not always hopitalized • Vancomycin • Linezolid • Daptomycin • Telavancin • Clindamycin • Ceftaroline

  13. Management of Recurrent MRSA SSTI • Personal hygiene and wound care • Avoid sharing personal items • Consider cleaning high-touch surfaces with commercially available cleaners

  14. When to Decolonize • Recurrent SSTI despite optimal hygiene • Ongoing transmission in close contacts

  15. Decolonization Strategies • Nasal mupirocin 2% BID for 5-10 days • Chlorhexidine baths or wipes for 5-14 days • Dilute bleach baths (1 tsp per gallon or ¼ cup per ¼ tub) for 15 mins. twice a week for 3 mos. • Consider oral abx if this fails • If interpersonal transmission suspected eval and rx contacts

  16. When to culture • If sick or not responding or treated with abx or suspected cluster. • Not for surveillance or post-treatment f/u

  17. MRSA Bacteremia • High morbidity and mortality (37% in SBE) • Must first decide if it is complicated or not.

  18. Uncomplicated Bacteremia • Positive blood cultures • SBE excluded • No implanted prostheses • Negative follow up blood cultures at 2-4 days • Defervescence with in 72 hr. of effective rx • No metastatic foci • Use vancomycin or daptomycin (6mg/kg) for at least 14 days

  19. Complicated Bacteremia • Positive blood cultures but don’t meet criteria for uncomplicated • Treat 4-6 wks with vanco or dapto (?8-10 mg/kg) • If SBE treat 6 wks • Do not add gent or rifampin to vanc for bacteremia or native valve SBE

  20. Complicated Bacteremia • Look for source, other sites, debridable? • Follow up blood cultures • Echo heart (TEE preferred)

  21. SBE – Native Valve Consider replacement if: Veg is > 10 mm 1 embolic event in 1st 2 week Valve failure CHF Abscess Persistent bacteremia or fever

  22. SBE – Prosthetic Valve • Vanc plus rifampin (300 mg tid) for at least 6 weeks plus gent (1 mg/kg/dose q 8) for 2 weeks • Early evaluation for valve replacement

  23. MRSA Pneumonia • For Severe community acquired pneumonia* empiric treatment should include MRSA coverage. *ICU, Cavities, empyema • For Healthcare associated pneumonia or documented MRSA Vanco or Linezolid or Clinda (if susceptible) for 7-21 days. • Daptomycin is not useful as it is inactivated by pulmonary surfactant

  24. MRSA Osteomyelitis • MRI is imaging modality of choice • Surgical debridement is the mainstay of therapy • Abx. options: Vancomycin Daptomycin TMS (4mg/kg of trimeth BID) + Rifampin 600/d Linezolid Clindamycin

  25. Duration of Therapy • Optimal duration is unknown • Minimum of 8 weeks (some say 1-3 mos more of oral rifampin with TMS, doxy, clinda, or FQ

  26. Septic Joint - Native • Drainage or debidement of joint space should always be performed • Same abx. as for osteo • Treat 3-4 wks.

  27. Device-Related Osteoarticular Infections • Early onset (< 2 mos. Post op or acute hematogenous seeding) AND • Stable implant AND • < 3 wks of sxs: initiate parenteral abx (like osteo) PLUS rifampin 600mg daily • Treat 2 wks iv then 3-6 mos po? • For spinal implants…treat until fused

  28. MRSA – Bone and JointAdditional Considerations • Individual patient circumstances matter • Failure rates with vanco may be 35-40% • If pts have concurrent bacteremia, add rifampin only after clearance of the bacteremia.

  29. Vancomycin Dosing • MIC “creep” has led to changes • 15-20 mg/kg (actual body wt.) q 12 h if nl renal fxn. (not more than 2 gm/dose) • If very ill consider loading dose of 25-30 mg/kg • Monitor troughs…shoot for 15-20

  30. How to factor in the MIC • If MIC < 2 pt’s clinical response should determine whether vanco is continued • If pt has not had clinical or microbiologic response then change therapy whatever MIC is. (high dose daptomycin @ 10 mg/kg/day plus a second agent such as gent, rif, linezolid, TMS, beta-lactam) Also consider telavancin. • We have seen dapto resistance emerge on rx.

  31. Antibiotic Notes • Vancomycin: Kills slower than Beta-lactams Clearly inferior to Beta-lactams for MSSA Variable tissue penetration High failure rate with MIC > 1 (CID 2011: 52 p969-974 and p975-981)

  32. Antibiotic Notes - Daptomycin • Breakpoint <= 1 • Prior exposure to vanco and higher vanco mic’s associated with higher dapto mic’s • CPK may elevate…dose-related • Eosinophilic pneumonia

  33. Antibiotic Notes - Telavancin • Bactericidal vs. MRSA, VISA, VRSA • May be more nephrotoxic than Vanco • No levels • Follow creatinine

  34. Antibiotic Notes - Tigecycline • Not included in guidelines due to an FDA warning indicating higher all-cause mortality in patients treated with tigecycline vs comparator drugs.

  35. Antibiotic Notes - Ceftaroline • New cephalosporin with activity vs MRSA • Has aerobic GNB activity about like ceftriaxone (ie no pseudomonas coverage) • BID dosing • Niche to be defined (? Lung data) • Role in SSTI unclear since no advantage over vancomycin

  36. Mupirocin • Cochrane report: reduced nosocomial S. aureus infections. Mostly those undergoing surgery or dialysis. • One small study showed decreased MSSA recurrences • Resistance is a concern

More Related